Concerns over Lung Cancer drive Development of Novel Therapeutics

Research and Markets have announced the addition of Lung Cancer: Novel Therapeutics with Potential to Drive Market Success report to their offering.

(PRWEB) November 13, 2003 --
Lung Cancer: Novel Therapeutics with Potential to Drive Market Success

Lung cancer is the second most commonly occurring non-cutaneous cancer and the leading cause of cancer deaths in the United States. Worldwide the incidence rates vary; however, lung cancer remains a leading cause of cancer mortality-reported by the World Health Organization to have caused 1.1 million deaths in 1997. Current treatments are, for the most part, ineffective; the five-year survival rate for lung cancer patients has remained unchanged at 14% for the last twenty years.

Lung cancer is a disease with a dismal prognosis. Patients usually have advanced disease at diagnosis. New therapeutic options range from modifications of conventional drugs that improve their pharmacokinetic properties to novel classes of drugs such as antisense molecules, anti-angiogenic agents, and drugs that induce targeted apoptosis. As these innovative solutions complete the regulatory process, the options for lung cancer patients will expand, and hopefully, for the first time in more than twenty years, the mortality figures will improve.

This Lung Cancer Market Analysis Report will detail the current and future potential treatments for this deadly disease. Additionally, the Report analyzes the future in detection and screening.

Unique Benefits of the Report Include:

1. Discussion of the causes and pathology of lung cancer, providing a vital overview of the disease

2. Analysis of the current therapeutic options and in-depth discussion on promising experimental approaches, detailing existing and emerging trends

3. In-depth company profiles outlining the business focus, contributions to the field, and research and development pipelines, giving a clear competitive landscape for potential collaborations and business strategies

4. Discussion of the most promising products in late-stage development, giving insight into the next generation of lung cancer pharmaceuticals

For a complete index of this report click on http://www.researchandmarkets.com/reports/39147

About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com
###